NDA 050786 · Labs Juvise
Pylera
Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hydrochloride · Oral · Nitroimidazole Antimicrobial
NovelLast checked: Nov 19, 2026Latest source record: Nov 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Sep 28, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
59
9 Phase 3, 6 recruiting
FAERS reports
1,133
940 serious, 18 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POTENTIAL FOR CARCINOGENICITY Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans [see Warning and Precautions (5.1) ]. WARNING: POTENTIAL FOR CARCINOGENICITY See full prescribing information for complete boxed warning. Metronidazole has been shown to be carcinogenic in mice and rats. It is unknown whether metronidazole is associated with carcinogenicity in humans ( 5.1 ).
What it is approved for
From the label in effect Jun 29, 2026.
PYLERA is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Eradication of Helicobacter pylori in Patients with Active Duodenal Ulcer or History of Duodenal Ulcer Disease PYLERA in combination with omeprazole are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori . The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of PYLERA and other antibacterial drugs, PYLERA should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: PYLERA is a combination of antibacterial agents (metronidazole and tetracycline hydrochloride) and bismuth subcitrate potassium [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 28, 2006 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelReviewLetter
1 products under this application
- PYLERA · BISMUTH SUBCITRATE POTASSIUM 140MG; METRONIDAZOLE 125MG; TETRACYCLINE HYDROCHLORIDE 125MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Bismuth Subcitrate" as an intervention, any sponsor and status, largest first.
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled TrialPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06943794 · 4,824 participants (planned) · Start Mar 30, 2026 · Primary completion May 1, 2030
Drug: recommendations for Hp eradication treatment · For: Gastric (Stomach) Cancer
Sites: Tongling, China
- Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori InfectionPivotal-lookingStatus unknown
National Taiwan University HospitalAcademic, hospital or other
NCT01906879 · 1,620 participants (planned) · Start Jun 2013 · Primary completion Dec 2017
Drug: triple, quadruple, non-bismuth quadruple therapy · For: Helicobacter Pylori Infection
Sites: Chiayi City, Taiwan; Hsinchu, Taiwan; Kaohsiung City, Taiwan · 10 sites in all
- A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese ChildrenPivotal-lookingRecruiting
Ying HUANGAcademic, hospital or other
NCT03365609 · 1,440 participants (planned) · Start Sep 20, 2017 · Primary completion Oct 1, 2025
Drug: triple therapy; sequential therapy and 2 more · For: Helicobacter Infections
Sites: Shanghai, China
- Five Days Quadruple and Clarithromycin Containing Triple Therapy as Treatment for Helicobacter Pylori EradicationPivotal-lookingCompleted
The University of Hong KongAcademic, hospital or other
NCT01306786 · 800 participants · Start Nov 2008 · Primary completion Oct 2010
Drug: Quadruple therapy; Triple therapy · For: Helicobacter Pylori Infection
Sites: Hong Kong SAR, Hong Kong
- Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with MalesPivotal-lookingEnrolling by invitation
National Cheng-Kung University HospitalAcademic, hospital or other
NCT06509139 · 661 participants (planned) · Start Jul 9, 2024 · Primary completion Jul 31, 2032
Drug: Drug: Bismuth Subcitrate 120 MG Oral Tablet; Esomeprazole 40mg and 2 more · For: Helicobacter Pylori Infection; Sex; Bismuth Quadruple Therapy
Sites: Tainan, Taiwan
- Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori EradicationPivotal-lookingCompleted
National Taiwan University HospitalAcademic, hospital or other
NCT03897244 · 603 participants · Start May 30, 2019 · Primary completion Feb 11, 2025
Drug: High-dose dual therapy (rabeprazole, amoxicillin); Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate) and 1 more · For: Helicobacter Pylori Infection
Sites: Taipei, Taiwan
Seoul National University Bundang HospitalAcademic, hospital or other
NCT02373280 · 600 participants (planned) · Start Aug 2014 · Primary completion Apr 2027
Drug: 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole); 7 day tailored PPI triple therapy (clarithromycin-containing triple therapy) and 2 more · For: Helicobacter Infection
Sites: Seongnam-si, South Korea
- Metronidazole- Versus Tinidazole-Based Bismuth Quadruple Therapy for Helicobacter Pylori EradicationPivotal-lookingNot yet recruiting
University of Medicine and Pharmacy at Ho Chi Minh CityAcademic, hospital or other
NCT07746934 · 600 participants (planned) · Start Jul 27, 2026 · Primary completion Aug 27, 2027
Drug: Metronidazole; Tinidazole 500mg and 3 more · For: Helicobacter Pylori Infection
Sites: Ho Chi Minh City, Vietnam
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea123
- headache111
- diarrhoea102
- dizziness81
- faeces discoloured81
- asthenia76
- vomiting75
- off label use68
- pruritus61
- fatigue60
- abdominal pain upper55
- dyspnoea54
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 11 |
| 2009 | 18 |
| 2010 | 7 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 35 |
| 2014 | 46 |
| 2015 | 73 |
| 2016 | 80 |
| 2017 | 83 |
| 2018 | 106 |
| 2019 | 86 |
| 2020 | 113 |
| 2021 | 94 |
| 2022 | 81 |
| 2023 | 53 |
| 2024 | 81 |
| 2025 | 95 |
| 2026 | 66 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pylera (Bismuth/Metronid/Tetracycline)
2024 spending
$168K
Beneficiaries
514
538 claims
Per beneficiary
$327
$2.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,992,297 |
| 2021 | $3,871,579 |
| 2022 | $4,439,708 |
| 2023 | $1,990,221 |
| 2024 | $168,132 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systematic Review and Meta-Analysis: Bismuth Enhances the Efficacy for Eradication of Helicobacter pylori.
Reum Choe A, Tae CH, Choi M, et al. · Helicobacter 2024 · Meta-Analysis, Systematic Review
- Quadruple therapy versus standard triple therapy for eradication of Helicobacter pylori in Kuwait.
Alboraie M, Saad M, Al-Ali J, et al. · Arab J Gastroenterol 2015 · Randomized Controlled Trial
- Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy.
Lerang F, Moum B, Haug JB, et al. · Scand J Gastroenterol 1997 · Clinical Trial, Clinical Trial, Phase I
- Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication.
Ecclissato C, Marchioretto MA, Mendonça S, et al. · Helicobacter 2002 · Clinical Trial, Randomized Controlled Trial
- Randomized comparison of two rescue therapies for Helicobacter pylori infection.
Wu DC, Hsu PI, Chen A, et al. · Eur J Clin Invest 2006 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Bismuth-based therapies for the first step eradication of Helicobacter pylori.
Sezgin O, Altintaş E, Uçbilek E, et al. · Turk J Gastroenterol 2006 · Randomized Controlled Trial
Sponsor: Labs Juvise
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.